INTRODUCTION: One of the most common and important side effects of 5-fluorouracil (5-FU) is mucositis with ulcerations in the oral cavity. We investigated the effects of local cryotherapy on mucositis incidence administrated durng 5-FU treatment. METHODS: In a total of 99 courses, 5-FU and folinic acid combination chemotherapy was given to 40 patients. In our study, we considered every course as a single case, and cryotherapy was given to the same patient in one course but not given in the next. RESULTS: While mucositis developed in 6.7% of the courses given with cryotherapy, this ratio was 38.9% in courses given without cryotherapy. In the logistic regression analysis, development of mucositis had been found to correlate only with cryotherapy. Odds ratio (OR) = 11.5; in the 95% confidence interval (CI) = 3.2 - 41.9; (p = 0.001). DISCUSSION: Results of initial studies evaluating the effects of cryotherapy in preventing mucositis due to 5-FU based chemotherapy regimens were promising. We concluded that oral cooling prevents 5-FU induced mucositis. This effective prophylactic treatment should be used in patients who are at increased risk for developing 5-FU induced mucositis.
INTRODUCTION: One of the most common and important side effects of 5-fluorouracil (5-FU) is mucositis with ulcerations in the oral cavity. We investigated the effects of local cryotherapy on mucositis incidence administrated durng 5-FU treatment. METHODS: In a total of 99 courses, 5-FU and folinic acid combination chemotherapy was given to 40 patients. In our study, we considered every course as a single case, and cryotherapy was given to the same patient in one course but not given in the next. RESULTS: While mucositis developed in 6.7% of the courses given with cryotherapy, this ratio was 38.9% in courses given without cryotherapy. In the logistic regression analysis, development of mucositis had been found to correlate only with cryotherapy. Odds ratio (OR) = 11.5; in the 95% confidence interval (CI) = 3.2 - 41.9; (p = 0.001). DISCUSSION: Results of initial studies evaluating the effects of cryotherapy in preventing mucositis due to 5-FU based chemotherapy regimens were promising. We concluded that oral cooling prevents 5-FU induced mucositis. This effective prophylactic treatment should be used in patients who are at increased risk for developing 5-FU induced mucositis.
Authors: C L Loprinzi; C Ghosh; J Camoriano; J Sloan; P D Steen; J C Michalak; P L Schaefer; P J Novotny; J B Gerstner; D F White; A K Hatfield; S K Quella Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: C L Loprinzi; S G Cianflone; A M Dose; P S Etzell; N L Burnham; T M Therneau; L Hagen; D K Gainey; M Cross; L M Athmann Journal: Cancer Date: 1990-04-15 Impact factor: 6.860
Authors: K H Chi; C H Chen; W K Chan; K C Chow; S Y Chen; S H Yen; J Y Chao; C Y Chang; K Y Chen Journal: J Clin Oncol Date: 1995-10 Impact factor: 44.544
Authors: M J Dodd; P J Larson; S L Dibble; C Miaskowski; D Greenspan; L MacPhail; W W Hauck; S M Paul; R Ignoffo; G Shiba Journal: Oncol Nurs Forum Date: 1996-07 Impact factor: 2.172
Authors: P Fidler; C L Loprinzi; J R O'Fallon; J M Leitch; J K Lee; D L Hayes; P Novotny; D Clemens-Schutjer; J Bartel; J C Michalak Journal: Cancer Date: 1996-02-01 Impact factor: 6.860
Authors: A Berger; M Henderson; W Nadoolman; V Duffy; D Cooper; L Saberski; L Bartoshuk Journal: J Pain Symptom Manage Date: 1995-04 Impact factor: 3.612
Authors: B Labar; M Mrsić; Z Pavletić; V Bogdanić; D Nemet; I Aurer; I Radman; N Filipović-Grcić; D Sertić; S Kalenić Journal: Bone Marrow Transplant Date: 1993-05 Impact factor: 5.483
Authors: D J Mahood; A M Dose; C L Loprinzi; M H Veeder; L M Athmann; T M Therneau; J M Sorensen; D K Gainey; J A Mailliard; N L Gusa Journal: J Clin Oncol Date: 1991-03 Impact factor: 44.544
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Douglas E Peterson; Kerstin Ohrn; Joanne Bowen; Monica Fliedner; Judith Lees; Charles Loprinzi; Takehiko Mori; Anthony Osaguona; Dianna S Weikel; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-09-21 Impact factor: 3.603
Authors: E Topuz; D Derin; G Can; E Kürklü; S Cinar; F Aykan; A Cevikbaş; R Dişçi; Z Durna; B Sakar; S Saglam; H Tanyeri; G Deniz; U Gürer; F Taş; N Guney; A Aydiner Journal: Invest New Drugs Date: 2008-09-02 Impact factor: 3.850
Authors: Paula Elaine Diniz Dos Reis; Marcia A Ciol; Nilce Santos de Melo; Paulo Tadeu de Souza Figueiredo; André Ferreira Leite; Natália de Melo Manzi Journal: Support Care Cancer Date: 2016-05-17 Impact factor: 3.603
Authors: Axel Grothey; Alex A Adjei; Steve R Alberts; Edith A Perez; Kurt A Jaeckle; Charles L Loprinzi; Daniel J Sargent; Jeff A Sloan; Jan C Buckner Journal: Semin Oncol Date: 2008-10 Impact factor: 4.929
Authors: M Elvira P Correa; Karis Kin Fong Cheng; Karen Chiang; Abhishek Kandwal; Charles L Loprinzi; Takehiko Mori; Carin Potting; Tanya Rouleau; Juan J Toro; Vinisha Ranna; Anusha Vaddi; Douglas E Peterson; Paolo Bossi; Rajesh V Lalla; Sharon Elad Journal: Support Care Cancer Date: 2019-12-14 Impact factor: 3.603
Authors: Philip Riley; Anne-Marie Glenny; Helen V Worthington; Anne Littlewood; Jan E Clarkson; Martin G McCabe Journal: Cochrane Database Syst Rev Date: 2015-12-23